search button
Open Access

Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B

  • Authors:
    • Yang Wang
    • Shuang Liu
    • Yu Chen
    • Sujun Zheng
    • Li Zhou
    • Fengmin Lu
    • Zhongping Duan

  • View Affiliations

  • Published online on: April 6, 2016     https://doi.org/10.3892/etm.2016.3230
  • Pages: 2293-2299

  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Adefovir (ADV) sequential monotherapy was included in the 2005 Asia-Pacific guidelines for the management of patients with lamivudine (LAM) resistance. However, following the development of ADV resistance, the proportion of resistant variants during combined rescue therapy with ADV and entecavir (ETV) were unknown. The present study characterized the dynamics of resistant variants in patients with chronic hepatitis B (CHB) and LAM‑resistant variants during antiviral therapy consisting of ADV monotherapy followed by ADV‑ETV combination therapy. A total of 3 patients were selected from a cohort of 55 patients with CHB due to developing ADV resistance. The patients had been previously treated with LAM (100 mg daily) for 21‑24 months. At the initiation of sequential monotherapy with ADV, LAM‑resistant variants (rtM204V/I and rtL180M) were detected in the three patients. These patients developed ADV resistance during 19‑30 months of ADV sequential monotherapy, and then switched their antiviral regimen to ADV‑ETV combination therapy. During ADV monotherapy and ADV‑ETV combination therapy, the patients were monitored every 3 months for the first year of therapy, and then every 6 months thereafter. A total of 30 serum samples were collected from the patients throughout the monitoring period. In total, 10 mutants that were associated with commonly‑used antiviral drugs were detected by pyrosequencing. During ADV sequential monotherapy, LAM‑resistant variants were gradually decreased, whereas ADV-resistant rtA181V/T and rtN236T variants gradually increased in the viral population. During 30‑41 months of ADV-ETV combination therapy, viral load reduction was 2.59‑3.28 log10 copies/ml; ADV‑resistant variants rtA181T/V and rtN236T were undetectable following 11‑24 months of combination therapy; and rtL180M and rtM204I/V remained dominant in the viral population. In conclusion, the results of the present study suggested that, in patients with LAM and ADV‑resistant variants that developed during LAM‑ADV sequential monotherapy, ETV‑ADV combination therapy may partially inhibit the replication of HBV DNA; however, LAM‑resistant rtL180M and rtM204I/V variants remained predominant following 30-41 months combination therapy.
View Figures
View References

Related Articles

Journal Cover

June-2016
Volume 11 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Liu S, Chen Y, Zheng S, Zhou L, Lu F and Duan Z: Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med 11: 2293-2299, 2016
APA
Wang, Y., Liu, S., Chen, Y., Zheng, S., Zhou, L., Lu, F., & Duan, Z. (2016). Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Experimental and Therapeutic Medicine, 11, 2293-2299. https://doi.org/10.3892/etm.2016.3230
MLA
Wang, Y., Liu, S., Chen, Y., Zheng, S., Zhou, L., Lu, F., Duan, Z."Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B". Experimental and Therapeutic Medicine 11.6 (2016): 2293-2299.
Chicago
Wang, Y., Liu, S., Chen, Y., Zheng, S., Zhou, L., Lu, F., Duan, Z."Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B". Experimental and Therapeutic Medicine 11, no. 6 (2016): 2293-2299. https://doi.org/10.3892/etm.2016.3230